Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study

Gacci, Mauro; Cai, Tommaso; Siena, Giampaolo; Minervini, Andrea; Torshizi, Mozhgan Fayaz; Bartolini, Matteo; Giannì, Gianluca; Saieva, Calogero; Ceroti, Mauro; Detti, Beatrice; Livi, Lorenzo; Pupi, Alberto; Carini, Marco

doi:10.3109/21681805.2013.846936

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pooled detection rate increased to 65% when PSA doubling time was 6 months or less and to 71 and 77% when PSA velocity was higher than 1 or higher than 2 ng/ml/year, respectively. During the last year, several studies have been published with choline PET/CT describing optimization of technique [33][34][35][36][37][38][39][40], and staging [41][42][43][44][45], restaging [46][47][48][49][50][51][52][53][54], radiation treatment planning [55 & ,56], and evaluation of treatment response [57]. Furthermore, two studies reported a prognostic value of choline PET/CT [58,59 & ].…”

Section: Cholinementioning

confidence: 99%

Advances in imaging modalities in prostate cancer

Bouchelouche

Türkbey²,

Choyke³

2015

Current Opinion in Oncology

View full text Add to dashboard Cite

Several advances in the imaging of PCa have been made during the past year. In particular, important clinical developments have been reported in multiparametric MRI, PET/computed tomography, and PET/MRI. The continuing development of imaging techniques in PCa has the potential to optimize treatment of PCa. However, the optimal imaging strategies for each of the major clinical scenarios in PCa have not yet been identified.

show abstract

Section: Cholinementioning

confidence: 99%

Advances in imaging modalities in prostate cancer

Bouchelouche

Türkbey²,

Choyke³

2015

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

“…Gacci and colleagues in a longitudinal study of 103 patents with biochemical recurrence showed that an increase in serum PSA from baseline by greater than 5 ng/mL, decrease in PSA doubling time by less than 6 months, and increase in PSA velocity by greater than 6 ng/mL/month were highly associated with the outcome of progression on the follow-up PET/CT (6 months after baseline PET/CT) [57]. …”

Section: Prognosticationmentioning

confidence: 99%

Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer

Jadvar

2016

Abdom Radiol

View full text Add to dashboard Cite

Prostate cancer is a prevalent public health problem worldwide. While imaging has played a major role in this disease, there still remain many challenges and opportunities. Positron emission tomography with various physiologically based radiotracers is fundamentally suited to interrogate this biologically and clinically heterogeneous disease along the course of its natural history. In this article, I review briefly the published evidence for the use of positron emission tomography with 18F-fluorodeoxyglucose, 11C-acetate, and 18F- or 11C-choline in the imaging evaluation of prostate cancer. Although the focus of the article will be on these radiotracers given the accumulated experience with them, but I will also comment on the outlook for the use of other emerging PET radiotracers such as those targeted to the prostate-specific membrane antigen and the amino acid metabolism pathway. It is anticipated that PET will play major role in the evaluation of prostate cancer in the current evidence-based medicine environment. There will also be exciting novel prospects for the use of therapeutic-diagnostic (theransotic) pairs in the management of patients with prostate cancer.

show abstract

“…Gacci and colleagues performed a longitudinal study of 103 consecutive patents who had 2 PET/CT scans, one at baseline and one after 6 months from the baseline scan (83). The authors found that increase in serum PSA from baseline by greater than 5 ng/mL, decrease in PSA doubling time by less than 6 months, and increase in PSA velocity by greater than 6 ng/mL/month were highly associated with the outcome of progression on the follow-up PET/CT.…”

Section: Imaging As a Prognostic Toolmentioning

confidence: 99%

Prognostic Utility of PET in Prostate Cancer

Jadvar

2015

PET Clinics

View full text Add to dashboard Cite

Accurate prediction and assessment of relevant outcomes is important in clinical trial design and in clinical practice for selecting and sequencing appropriate individualized management of patients with prostate cancer. There have been many standard non-imaging based prediction tools for the various phases of prostate cancer. However these tools may be limited in individual cases and need updating based on the improved understanding of the underlying complex biology of the disease and the emergence of the novel targeted molecular imaging methods. A new platform of automated predictive tools that combine the independent molecular, imaging, and clinical information can contribute significantly to patient care and improve outcome. Such platform will also be of interest to regulatory agencies and payers as more emphasis is placed on supporting those interventions that have quantifiable and significant beneficial impact on patient outcome.

show abstract

Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study

Abstract: PSA kinetics is strictly related to (18)FC PET/CT findings. In patients with biochemical relapse, ΔPSA >5 ng/ml, PSAdt <6 months and vPSA >6 ng/ml/month are highly predictive of (18)FC PET/CT features worsening, independently from the treatment received.

Cited by 4 publications

References 26 publications

Advances in imaging modalities in prostate cancer

Advances in imaging modalities in prostate cancer

Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer

Prognostic Utility of PET in Prostate Cancer

Contact Info

Product

Resources

About